Chardan Capital Reiterates “Buy” Rating for iBio (NYSE:IBIO)
Chardan Capital reiterated their buy rating on shares of iBio (NYSE:IBIO – Free Report) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $5.00 target price on the stock. Separately, Wall Street Zen upgraded iBio to a “sell” rating in a report on Tuesday, March 18th. Check Out Our Latest […]
Chardan Capital reiterated their buy rating on shares of iBio (NYSE:IBIO – Free Report) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $5.00 target price on the stock. Separately, Wall Street Zen upgraded iBio to a “sell” rating in a report on Tuesday, March 18th. Check Out Our Latest […]
